Europe Biosimilar Market Analysis, Size, Share and Report 2025-2033

`

Europe Biosimilar Market Outlook

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Size in 2024: USD 13,864 Million

Market Forecast in 2033: USD 59,733.3 Million

Market Growth Rate: 17.1% (2025-2033)

The Europe biosimilar market was valued at USD 13,864 Million in 2024 and is projected to grow to USD 59,733.3 Million by 2033, with an expected compound annual growth rate (CAGR) of 17.1% from 2025 to 2033.

For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample

Europe Biosimilar Market Trends:

The market in Europe is mainly inspired by increasing demand for cheap treatment, especially among patients with chronic diseases. With that, the prevalence of biologics near the patent expiration is increasing the amount of biosimiller, so expanding the market. In addition, the growth of healthcare infrastructure across the region is allowing more and more of biosmillar, various health officials have already implemented a favorable regulatory structure. And quickly inflated health care expenses within Europe create opportunities for patients and providers to have options with biosimiller.

Similarly, increasing focus on reducing total healthcare expenditure is an important contributor to the development of biosimiller. They provide saving on comparable effectiveness for treatment options. In addition, there are many major governments and health bodies that produce benefits for cosmic biosimillars, this act has significant development implications in itself. In addition, increasing levels of awareness campaigns to educate the effectiveness of biosimiller and their safety are promoting acceptance between both healthcare physicians and their patients. There is even more prominence and validity for the market, to create strategic tricks to join biosimiller through research and development with more pharmaceutical companies.

Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C

Europe Biosimilar Market Scope and Growth Analysis:

The market potential is rapidly expanding as therapeutic applications in oncology, immunology, and endocrinology satisfy unmet clinical needs. In addition, greater use of biosimilars in hospitals encourages their adoption in usual care and solidifying the market landscape. It is important to note that the growing availability of lower-cost biosimilar drugs is increasing access to therapies, specifically in developing countries in Europe. Furthermore, the strong collaboration among regulators and stakeholders is creating a streamlined pathway to license and launch biosimilars.

The expanding pool of local manufacturers in Europe is fostering a great amount of market diversity to accommodate local market needs. Additionally, the use of advances manufacturing technologies is aiding with efficiencies in the supply chain and lower production costs. Moreover, there is growing focus on biosimilar interchangeability, which is assuring prescribers and will further facilitate an even larger market acceptance. According to the market analysis, the evolving reimbursement policies supporting the adoption of biosimilars are enhancing the market outlook and improving the landscape for actors in the industry and healthcare systems.

IMARCs report provides a deep dive into the Europe biosimilar market analysis, outlining the current trends, underlying market demand, and growth trajectories.

By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:

• Novartis
• Pfizer
• Teva 
• Celltrion 
• Merck Sharp & Dohme
• Samsung Bioepis 
• Eli Lilly
• Accord Healthcare Ltd.
• Amgen
• Boehringer Ingelheim
• Hexal Ag 
• Apotex 
• Stada Arzneimittel Ag
• Ratiopharm
• Mylan

Europe Biosimilar Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.

Breakup by Molecule:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab

Breakup by Indication:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility

Breakup by Manufacturing Type:

• In-house Manufacturing
• Contract Manufacturing

Breakup by Country:

• Italy
• Germany
• United Kingdom
• France
• Spain
• Rest of Europe

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145

`